Arrowhead Pharmaceuticals (ARWR) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Arrowhead Pharmaceuticals, as the data feed reports them.

Analysts' mean target, 14 analysts
$105.86
146.2% above the price

The 14 analysts reported by the data feed have a mean price target for Arrowhead Pharmaceuticals of $105.86, 146.2% above the $42.99 price (range $73.00–$126.00). 11.40% of the float was sold short as of Oct 30, 2026. Institutions hold 86.8% of the shares and insiders 3.7%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$105.86+146.2% vs price
Analysts
14
Short interest
11.40%of float, Oct 30, 2026
Short ratio
6.68 days
Institutions
86.8%
Insiders
3.65%
Beta
1.37
Next earnings
Feb 4, 2027estimated

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

14 analysts covering Arrowhead Pharmaceuticals, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $42.99.

Analysts' price targets for Arrowhead Pharmaceuticals
Mean price target$105.86146.2% above the price (+146.2%)
Median price target$105.00144.2% above the price (+144.2%)
Highest target$126.00193.1% above the price (+193.1%)
Lowest target$73.0069.8% above the price (+69.8%)
Analysts with a target14

Ratings this month · 15 analysts

Strong buy 4(27%)Buy 10(67%)Hold 1(7%)
Analysts' ratings of Arrowhead Pharmaceuticals this month, by rating
RatingAnalystsShare
Strong buy427%
Buy1067%
Hold17%
Sell00%
Strong sell00%

The feed averages these to 1.4 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “strong buy”.

Who owns Arrowhead Pharmaceuticals

Ownership of Arrowhead Pharmaceuticals
Held by institutions86.8%656 institutions; percent of shares outstanding
Held by institutions, of the float90.1%
Held by insiders3.65%percent of shares outstanding
Shares outstanding141.37M
Float122.56Mshares available to trade
Insiders' net purchases, six months−1.72K1 purchases (11.88K shares), 2 sales (13.6K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Arrowhead Pharmaceuticals
Shares short11.58Mas of Oct 30, 2026
Percent of float11.40%shares short ÷ float
Percent of shares outstanding8.20%shares short ÷ shares outstanding
Short ratio (days to cover)6.68shares short ÷ average daily volume

Arrowhead Pharmaceuticals short interest from FINRA, with its history

Trading figures

Trading figures for Arrowhead Pharmaceuticals
Beta1.37movement against the market; 1 moves with it
52-week high$95.49
52-week low$37.06
Average volume, 3 months1.95Mshares a day
Average volume, 10 days2.65Mshares a day

Dates to know

Upcoming and recent dates for Arrowhead Pharmaceuticals
Next earnings reportFeb 4, 2027the feed's estimate, not confirmed

Questions and answers

What is the analysts' price target for Arrowhead Pharmaceuticals (ARWR)?

As reported by the data feed, the mean price target of the 14 analysts covering Arrowhead Pharmaceuticals is $105.86, 146.2% above the latest price of $42.99. The highest target is $126.00 and the lowest $73.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Arrowhead Pharmaceuticals stock?

Of the 15 ratings the data feed reports for the current month, 4 are strong buy, 10 buy, 1 hold, 0 sell and 0 strong sell.

How many Arrowhead Pharmaceuticals shares are sold short?

As reported by the data feed, 11.58M shares were sold short, 11.40% of the float as of Oct 30, 2026. At the average daily volume that is 6.68 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Arrowhead Pharmaceuticals stock?

As reported by the data feed, institutions hold 86.8% of the shares (656 institutions) and insiders 3.7%. There are 141.37M shares outstanding, of which 122.56M are in the float.

When is Arrowhead Pharmaceuticals's next earnings report?

The data feed lists Feb 4, 2027, marked as its estimate rather than a date the company has confirmed.

How much does Arrowhead Pharmaceuticals stock move with the market?

Its beta, as reported by the data feed, is 1.37: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $37.06 and $95.49.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals (ARWR) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/ARWR/statistics

Underlying data: Yahoo Finance.